NO (nitric oxide) may be involved in fluid homoeostasis. We hypothesized that increases in NO synthesis contribute to acute, saline-induced natriuresis, which, therefore, should be blunted when NO availability is stabilized. Young men were studied during simultaneous infusions of L-NAME [N G -nitro-L-arginine methyl ester; bolus of 750 μg · kg − 1 of body weight and 8.3 μg · min
INTRODUCTION
The mechanisms responsible for the physiological control of sodium balance are not clearly identified (reviewed in [1] ). After the classical experiments of Guyton and co-workers in the 1970s [2, 3] , it has been widely important controller of renal sodium excretion under normal conditions. Modest sodium loading may cause marked natriuresis without any change in arterial blood pressure, sometimes even against minor decreases in MABP (mean arterial blood pressure). In these situations, changes in blood pressure cannot be the primary signal to the kidney (reviewed in [1, 5] ).
Volume expansion leads to deactivation of the RAAS and natriuresis, and the former seems to be a necessary precondition for the latter [6] . The RAAS is believed to be regulated by parallel inputs to renin secretion via (i) renal arterial pressure, (ii) renal nerve activity to the juxtaglomerular cells mediated by β 1 -adrenoreceptors and (iii) the concentration of chloride in the tubular fluid at the macula densa. The composition of the tubular fluid at the macula densa is a complex function of GFR (glomerular filtration rate) and proximal tubular functions including glomerulo-tubular balance and TGF (tubulo-glomerular feedback) [7, 8] . Recent experiments (designed to identify renal nerve activity as the primary controller) showed unexpectedly that a large fraction of the homoeostatic control of secretion of the RAAS may be exerted by factors other than arterial blood pressure, GFR and signalling via β 1 -adrenoreceptors [9, 10] . This unexplained control element could include the rate of synthesis of NO. NO has multiple roles in the control of renal function, and its actions under physiological conditions are complex [11] . However, l-arginine [a substrate for NOSs (nitric oxide synthases)] increases renal blood flow, filtration rate and sodium excretion [12] , whereas inhibition of NOSs reduces RPF (renal plasma flow) and sodium excretion [13] . It seemed attractive to hypothesize that changes in NO synthesis play an important role in the corrective natriuresis in response to increases in body fluid volume.
We investigated the role of NO in the renal response to a modest sodium load proved not to affect arterial blood pressure or GFR [1] . Simple blockade of NO synthesis by a NOS inhibitor is unattractive because of the associated increases in peripheral resistance and arterial blood pressure. Therefore we combined the administration of l-NAME (N G -nitro-l-arginine methyl ester) with an infusion of SNP (sodium nitroprusside) adjusted to eliminate the increase in total peripheral resistance generated by the NOS inhibition. Under these conditions, we performed volume expansion with isoosmotic saline at a modest rate. Unexpectedly, NOclamping did not decrease the natriuretic response to volume expansion.
MATERIALS AND METHODS

Subjects and procedures
Nine healthy male volunteers [average age, 26 (range, 24-28) years; average height, 181 (range, 173-192) cm; and average body weight, 81 (range, 74-88) kg] were assigned to three separate experiments carried out in random order with intervals of at least 2 weeks. The subjects denied intake of any medication for 2 weeks prior to and during the investigation. The experiments were performed in accordance with the Declaration of Helsinki after approval by the Danish Medicines Agency (j. no. 2612-1988) and the regional scientific ethical committee (ref. no. 20020035 ). All participants gave written informed consent.
For 4 days prior to each experiment, the participants ingested a standardized low-salt diet containing up to 30 mmol of Na + · day − 1 . Compliance was checked by analysis of urine collected during the last 24 h. In the cases where daily excretion was higher than 40 mmol of Na + , the experiment was rejected. On the day of the study, the subjects presented at 07.50 hours having refrained from caffeine for the last 12 h. They were weighed and seated, and short catheters (Venflon 18G; Becton Dickinson) for infusions and blood sampling were inserted into the left and right superficial cubital veins respectively.
GFR was measured as the clearance of chromiumlabelled EDTA ( 51 Cr-EDTA; GE Healthcare). An intravenous bolus injection [27.8 kBq · kg − 1 of body weight) in 10 ml of 0.9 % NaCl] was administered, followed by a continuous intravenous infusion (1.04 MBq · h − 1 in 5.5 % glucose solution at 25 ml · h − 1 ). Effective RPF was measured by the clearance of PAH (paminohippurate; Merck). An intravenous priming dose of 10 mg · kg − 1 of body weight in 10 ml of 0.9 % NaCl was administered, followed by infusion of 1.65 g · h − 1 in 5.5 % glucose solution at 25 ml · h − 1 . Clearances of PAH and 51 Cr-EDTA were calculated as the rate of excretion divided by plasma concentration.
Electrodes for the measurement of ECG and ICG (impedance cardiogram) were applied at the neck and chest, and the ICG device (PhysioFlow PF-05; Manatec Biomedical) was started. Brachial blood pressure was measured every 10 min by the use of an automatic oscillometric sphygmomanometer (Colin Press-Mate BP-8800; ViCare Medical) transferring data to the ICG apparatus. Subjects ingested 400 ml of 10 % glucose hourly.
For each subject, three investigations were planned (for an overview, see Figure 1 ): (i) infusion of iso-osmotic NaCl solution for 3 h (n = 8; NaCl series), (ii) clamping of the NO level by simultaneous infusion of a NOS inhibitor and a NO donor for 5 h (n = 7; ClampCon series) and (iii) a series of combined interventions (n = 7; ClampNaCl series).
In the clamp series (ClampCon and ClampNaCl), administration of l-NAME (Merck Biosciences) was started at t = − 45 min with a priming dose of 750 μg · kg − 1 in 10 ml of saline, followed by continuous infusion of 8.3 μg · min − 1 · kg − 1 of body weight in 1 ml · min − 1 of 5.5 % glucose as described previously
Figure 1 Time line of the experimental protocol
Prep, preparation; Bas, baseline; Inf, infusion; Rec, recovery; Mon, monitoring; arrow with dot, blood sample; arrow with triangle, urine collection; BP, arterial blood pressure measurements; ICG, impedance cardiography; L-NAME, L-NAME infusion; SNP, SNP infusion. For details, see the text.
[14]. After 30 min (t = − 15 min), SNP (Abbott Laboratories) was added at a rate of 0.5 μg · min − 1 · kg − 1 of body weight in 5.5 % glucose, delivered at 5 ml · h − 1 by a syringe pump.
In the NaCl series (NaCl and ClampNaCl), a sodium load of 20 μmol · min − 1 · kg − 1 of body weight (7.8 ml of 0.9 % NaCl · h − 1 · kg − 1 of body weight) was given over 3 h (t = 60-240 min) by a volumetric infusion pump.
At time t = 300 min, l-NAME was withdrawn. The infusion of SNP was stopped after an additional 30 min. Blood and urine samples were obtained hourly. Urine was collected by voluntary micturition; the subject was allowed to stand during voiding if necessary.
Laboratory methods
Blood samples were centrifuged immediately at 4
• C. Plasma and urine samples were analysed at the end of the experiment by flame photometry (IL 943 Flame Photometer; Instrumentation Laboratory) and osmometry (model 3D3; Advanced Instruments) respectively. The activity of 51 Cr in plasma and urine was measured in a well counter (1480 Wizard; Wallac). Plasma and urine samples for the analysis of hormones, NO metabolites [NO x (combined nitrate + nitrite)], cGMP, PAH and creatinine were stored at − 20
• C. PRC (plasma renin concentration) was assessed by the antibody trapping method of Poulsen and Jorgensen [15] and the activity was standardized to the World Health Organization International Reference Reagent (Human Renin; National Institute for Biological Standards and Control, Potters Bar, Herts., U.K.), which was analysed in each assay run. The results are expressed in terms of mIU (milli-international units) · l − 1 . Concentrations of peptide hormones in plasma were measured by RIA using specific antibodies and 125 Ilabelled tracer after extraction using Sep-Pak C 18 columns (Waters, Millipore, Milford, MA, U.S.A.) [16] . Immunoreactivity of AngII (angiotensin II) in plasma extracts was measured using the antibody Ab-5-030682 as described previously [6] and 125 I-labelled AngII (kindly provided by Department of Clinical Physiology, Glostrup Hospital, Glostrup, Denmark). Vasopressin immunoreactivity was determined by the use of an antibody (AB3096) produced in this laboratory [17] . The concentration of aldosterone was measured with a commercial RIA kit (Coat-A-Count; Diagnostic Products, Los Angeles, CA, U.S.A.).
Quantification of NO x was performed with a commercial kit (850-001-KI01, Nitrate/Nitrite Colorimetric Assay kit; Cayman Chemical) by the use of a conventional plate reader (Elx808; Biotek Instruments).
A commercial kit (Biotrak cGMP Enzyme Immunoassay; GE Healthcare) was used for the determination of concentrations of cGMP.
PAH and creatinine concentrations were determined by conventional spectrophotometry.
Statistics
The results are presented as means + − S.E.M. Differences between mean values at the baseline between the three groups were assessed by one-way ANOVA with pairwise comparisons based on the Tukey-Kramer method. The development over time within each series was analysed by a repeated measurement ANOVA using a random intercept model with an AR(1) error structure using PROC MIXED. Pairwise comparisons between all time points and the baseline were made using the TukeyKramer method to adjust for multiple comparisons. To take random baseline imbalances between the groups into account, comparisons of the two NaCl groups are based on dividing each measurement with the baseline value of each individual. The comparison is then based on a repeated measurement ANOVA of the remaining time points using the same model as above.
In presenting our results for the single outcome measures, we start by focusing on differences between the baseline measurements and values obtained during or after the infusion in each series. Then we report on testing for systematic differences in the overall course between the two NaCl series.
RESULTS
The slow saline loading was carried out under steadystate conditions of low sodium intake. On day 4 of the diet, baseline rates of urinary sodium excretion were low (ClampCon: 10 + − 3; ClampNaCl: 12 + − 4; and NaCl: 13 + − 2 mmol · 24 h − 1 ), while the rates of potassium excretion were 7-10-fold higher (113 + − 8, 89 + − 9 and 112 + − 11 mmol · 24 h − 1 in ClampCon, ClampNaCl and NaCl respectively). One participant was excluded on the basis of apparent lack of compliance with the diet (24 h sodium excretion rates of 48 and 42 mmol on separate occasions). Data from eight participants are reported; six subjects underwent all of the procedures.
Natriuretic response
The saline loading increased renal sodium excretion ( Figure 2 and Table 1 ). Without NO-clamping (NaCl series), the rate of sodium excretion within the infusion period showed a strong tendency towards an increase when compared with the baseline (from 23 + − 5 to 30 + − 6 μmol · min − 1 , P ∼ 0.06), and the excretion rate after the infusion (35 + − 7 μmol · min − 1 ) was increased significantly compared with the first hour of infusion (P < 0.05). When the same saline load was administered during NO-clamping (ClampNaCl series), there was a robust increase in the rate of sodium excretion (from 19 + − 5 to 54 + − 10 μmol · min − 1 post-infusion, P < 0.001). Without NO-clamp, the change in sodium excretion was approx. 50 %. During NO-clamping, sodium excretion rose by a factor of 3 ( Figure 2 ), and the difference between the two series is highly significant (P < 0.0001).
The baseline values of sodium excretion and of filtered load of sodium in the two sessions were similar (Table 1) . Thus, during NO-clamping, the sodium loading elicited a natriuretic response markedly larger than that measured without clamping ( Figure 2 ).
Other renal functions
Clamping of NO itself was associated with a decrease in RPF (Table 1) ; during NO blockade, the RPF at baseline was 24 % smaller (P ∼ 0.02) than the corresponding value obtained in the absence of l-NAME (Table 1) . Clamping of NO did not change the baseline values of GFR or filtered load of sodium (hereafter referred to as FiLoadNa + ; NaCl compared with ClampNaCl and ClampCon; see Table 1) .
Neither with or without NO-blockade did the saline loading change RPF (Table 1) ; there was not even a tendency towards an increase. In addition, the FiLoadNa + and the GFR remained constant during the saline loading (Table 1 and Figure 2 ). Therefore changes in RPF, GFR or FiLoad-Na + do not appear to be involved in the present natriuretic responses. In terms of relative changes in GFR and FiLoad-Na + , the data from the clamp series showed a transient decrease during the saline loading (ClampNaCl compared with NaCl; FiLoadNa + : P < 0.02, GFR: P < 0.01, Figure 2) ; however, the decrease was relatively small and occurred only during the middle hour of infusion. In the absence of NOclamping, the saline loading increased the renal excretion of NO metabolites (NO x ) significantly (P < 0.02; Table 1 ) despite a fall in the plasma concentration (see below). The urinary excretion rate of cGMP did not change measurably during any of the three series of experiments (Table 1) . Fractional potassium excretion increased in all three studies in a very similar way (Table 1) .
In summary, NO-clamping itself decreased RPF, but did not change either the GFR or the FiLoad-Na + . Saline loading increased the rate of sodium excretion significantly more during NO-clamping than without NOclamping, i.e. NO-clamping is associated with hypernatriuresis. Saline loading did not increase RPF, GFR or FiLoad-Na + , either with or without NO-clamping. In contrast, transient decreases in GFR and FiLoad-Na + occurred during clamping. In other words, during NOclamping, the saline loading elicited hypernatriuresis despite sustained suppression of RPF and despite transient decreases in GFR and FiLoad-Na + . This pattern indicates that renal haemodynamic changes cannot explain the hypernatriuresis occurring during NO-clamping.
Hormones and other mediators
During saline loading without and with NO-clamping (NaCl and ClampNaCl respectively), PRC, plasma AngII and plasma aldosterone decreased simultaneously (Table 2 and Figure 3 ) and to very similar extents. Plasma AngII and aldosterone decreased by approx. 50 %. During the time control protocol (ClampCon), PRC, plasma AngII and plasma aldosterone did not change significantly. Plasma NO x concentrations showed (Table 2) . Plasma vasopressin showed no significant differences in any series. In summary, changes in renin system variables, vasopressin, NO metabolites and cGMP do not seem to be related to the hypernatriuresis.
Systemic haemodynamics
The experiments were designed to provide inhibition of NOS by l-NAME infusion under conditions of unaltered peripheral resistance. The results show that this goal was achieved as total peripheral resistance did not deviate significantly from the baseline values; for example, the final values of peripheral resistance in the NaCl and ClampNaCl series were 1.13 + − 0.04 and 1.15 + − 0.06 mmHg · s · ml − 1 respectively (Table 3) . MABP was measured every 10 min, and the results were averaged to hourly values. NO-clamping tended to reduce MABP (Table 3 ), but the 6-9 mmHg decreases in mean baseline values were not statistically significant. MABP did not deviate significantly from baseline during either of the saline loading protocols; the mean values showed trends towards decreases (2-6 mmHg) but none were statistically significant. A small decrease in MABP in the time control series was significant, but transient ( − 7 mmHg, ClampCon series, first two-third of infusion period; P < 0.05) ( Table 3) . Heart rates averaged 59-66 beats · min − 1 under baseline conditions in the different series; significant differences between or within the series could not be detected (Table 3) . Similarly, the baseline values of cardiac output were uniform (5.4-5.8 l · min − 1 ), and the cardiac output data did not show any differences within or between series (Table 3) . Therefore the saline loading was so slow that it was unable to produce measurable changes in MABP, heart rate and cardiac output with or without NO-clamping.
Side effects
During NO-clamping, most participants reported some degree of nausea and drowsiness. A total of five sessions were terminated prematurely and thus excluded from the data analysis. Remarkably, plasma vasopressin concentrations, normally sensitive to nausea, were constant during the sessions (Table 2) .
In summary, under conditions of stable haemodynamics, RPF, GFR and filtered sodium load, slow saline loading induced natriuresis along with a decrease in PRC, plasma AngII and plasma aldosterone. However, the increase in sodium excretion in response to the saline loading during NO-clamping (ClampNaCl) was three to four times that occurring without clamping (NaCl).
DISCUSSION
We hypothesized that stabilization of the systemic supply of NO by constant infusion of l-NAME in combination with SNP would limit the ability of the kidneys to respond to a modest saline load. Our results do not support this working hypothesis. Unexpectedly, the slow saline loading produced a clearly exaggerated natriuretic response during NO-clamping, a hypernatriuresis, despite no concurrent changes in arterial blood pressure, heart rate, cardiac output, RPF, GFR, filtered load of sodium and cGMP excretion and despite very similar excursions in renin system activity in plasma and plasma NO x levels. The hypernatriuresis is remarkable also because it occurred under conditions of constantly reduced renal blood flow and relatively low arterial blood pressure.
The reason for the hypernatriuresis during NOclamping is uncertain. It is possible that increases in the rate of NO synthesis do play an essential role in the normal natriuretic response to an increase in total body sodium, but that the design of the present study did not enable us to discover this role. Alternatively, the normal physiological adjustments of renal sodium excretion are independent of acute changes in the rate of NO synthesis in the kidney.
The model
NO may participate in the regulation of renal excretory function through several pathways. An increase in systemic NO availability decreases peripheral vascular resistance, reduces arterial blood pressure and, in this way, reduces sodium excretion. In contrast, increased availability of NO in the kidney reduces renal vascular resistance, decreases tubular sodium reabsorption and inhibits intrarenal control mechanisms such as TGF, thereby favouring the excretion of sodium. In humans, NO inhibition has been found to increase blood pressure by 7-10 % concomitant with robust decreases in RPF of 13-20 % [18-20] , and infusion of l-arginine, a NOS substrate, may increase RPF, GFR and sodium excretion in the absence of systemic haemodynamic changes [12] . It is a major advantage of the present model that the effects of stabilized NO availability throughout the body are measured at arterial blood pressures very similar to baseline.
It is evident that the intrarenal availability of NO, affecting the vasculature, the tubular transport and the intrarenal control systems, is not necessarily restored quantitatively by the present co-infusion of nitroprusside. In the kidney, nNOS (neuronal NOS) is expressed in the efferent arteriole, in the macula densa and in the medulla [21] [22] [23] , and eNOS (endothelial NOS) is present in the proximal tubule, the thick ascending part of the loop of Henle, and in the collecting ducts in addition to the vessels [22] . It is difficult to obtain data elucidating the local tensions of NO involved in the function of these structures. Therefore our results may reflect circumstances where local NO levels deviate from those of baseline, but it remains a valid assumption that the excursions in NO availability are limited under the present conditions. Several studies in normal humans have shown that acute inhibition of NO synthesis decreases renal sodium excretion [13, [24] [25] [26] [27] [28] . In addition, other findings may support the notion of a regulatory role of NO. Administration of l-arginine, a NOS substrate, increases sodium excretion [12, 29] and augments the renal response to volume expansion [30] . From such results it can be argued (i) that if NO is involved in the normal control of sodium excretion, then a slow volume expansion should increase NO production, and (ii) that stabilization of the supply of NO, therefore, should reduce the natriuretic response to this intervention. Although the renal effects of experimental perturbations of NO synthesis are clear, the role of NO in normal fluid homoeostasis has been very difficult to assess due to the concomitant, large changes in renal blood flow and GFR occurring during such perturbations.
The role of NO in sodium homoeostasis is likely to include an effect of NO on renin secretion. Although the conclusions from multiple studies of the effect of NO on renin secretion under physiological conditions are not completely unanimous, the data supporting the view that NO stimulates renin secretion appear strong [24, [31] [32] [33] [34] [35] . Therefore it seems that under in vivo conditions NO may accelerate both sodium excretion and renin secretion, i.e. it elicits natriuresis and activates a powerful antinatriuretic mechanism at the same time. Against this background, it appeared attractive to try to stabilize the systemic supply of NO and study the effects of modest saline loading on renin levels and sodium excretion with and without a stabilized NO supply. The variable with which to gauge the effect of l-NAME, and therefore to be used for adjustment of the rate of administration of NO donor, was vascular resistance. It was assumed that arterial blood pressure would not be an appropriate indicator of the l-NAME effects because blood pressure is heavily regulated by other control systems, and it was decided, therefore, to use total peripheral resistance as the l-NAME effect to be eliminated by administration of the NO donor [14] . The main methodological questions seem to be the extent of the blockade of NO synthesis in the kidney, and the somewhat related issue of sensitivity of the renal NOS isoforms relative to the eNOS of the peripheral circulation determining total peripheral resistance.
In humans, inhibition of NOS by infusion of l-NAME has been investigated by infusion of a wide range of doses from 1 μg · min − 1 · kg − 1 of body weight [24] to 133 μg · min − 1 · kg − 1 of body weight [36] for periods of 30 min [24, 36] , 40 min [13, 34, 35] , 60 min [37] and 90 min [25, 26] . Priming doses have not been applied in these investigations. As the onset of the effects of even large doses may be slow [37] , and the aim of the present study was to maintain a new steady state for hours, we applied bolus injection plus continuous infusion of l-NAME, quickly followed by continuous infusion of SNP.
There is no generally accepted method for the assessment of the systemic NOS activity. Exhaled amounts of NO may serve as an indicator [38] , but it is not clear to what extent this reflects the NO involved in vascular endothelial function [39] . In the absence of specific measures we can conclude only that judged from the single effect of the l-NAME on the total peripheral resistance ( + 33 %; [14] ), the protocol provided substantial, but probably incomplete inhibition of NOS activity. This leaves open the possibility that NOS located in different renal structures may be inhibited to different extents, but at present it is very difficult to assess such incompleteness of inhibition, particularly in healthy human subjects.
The hypernatriuresis
The main new finding is that the clamping of the NO supply was associated with a hypernatriuresis irrespective of a sustained decrease in RPF, and unaltered values of (and, if anything, decreasing trends in) arterial blood pressure and GFR. The significant reduction in RPF in combination with the clear trend towards reduction in arterial blood pressure would be expected to reduce the rate of sodium excretion. The hypernatriuresis occurred despite these antinatriuretic conditions, and inasmuch as the clamp-mediated changes in 'renal haemodynamics' favoured antinatriuresis, the results indicate that changes in tubular sodium reabsorption are the most likely cause(s) of the hypernatriuresis. l-NAME inhibits the NOSs, of which eNOS is expressed in the renal endothelial cells and nNOS predominantly in the macula densa cells. Both seem to be regulated by a variety of physiological stimuli (see the review by Kone [40] ). Endogenous NO may enhance proximal fluid reabsorption in normal human [25] , but under experimental conditions in rats it seems to promote excretion of sodium ions and water via an effect on medullary blood flow [41] [42] [43] [44] . This apparent discrepancy may be due to species-specific and/or environmental differences. Routine daily sodium intakes in rats scale up to very large sodium intakes in humans.
Although seeming to support the notion that the renal haemodynamic changes cannot be responsible for the observed effects, the present results must be interpreted with caution. The renal medullary circulation constitutes a minor fraction of the renal vascular bed, so that changes in renal haemodynamics specific to the medulla are unlikely to be detected by measurements of total renal blood flow by the clearance methods applied in the present study. The results of a recent study indicate that the renal medullary circulation is indeed particularly sensitive to changes in NO availability [45] . Interference with the NO supply to this relatively small region may have major effects on renal water and solute excretion to the extent that hypertension is generated by NOS inhibition and abrogated by infusion of excess substrate [41] [42] [43] [44] . Therefore the present results do not conclusively indicate that changes in tubular reabsorption are the cause of the observed hypernatriuresis. Changes in medullary haemodynamics may be a plausible cause of the present findings.
A significant secondary result, that NO-clamping did not reverse the l-NAME-mediated decrease in RPF, seems to indicate that the renal vascular bed is more sensitive to NOS inhibition by l-NAME than the remainder of the peripheral vasculature. Alternatively, the results show that the amount of NO required to return total peripheral vascular resistance to baseline is not able to revert renal vascular resistance. Previous results have been interpreted to indicate that in humans the renal vascular bed may be more sensitive to NO inhibition than other vascular beds [24] . The present data are compatible with this notion, but our design did not allow a detailed analysis of the changes in renal perfusion.
Contrary to our expectations, the present data do not contribute significantly to a clarification of the role of changes of NO availability in the homoeostatic response to slow saline loading. The finding that hypernatriuresis occurred under conditions of depressed RPF, constant arterial pressure and changes in systemic RAAS activity similar to those of control experiments indicates that mechanisms other than arterial pressure and systemic RAAS variables are important. If, in addition, it is considered unlikely that a functionally relevant increase in medullary flow occurred under the present 24 % decrease in total RPF, then the results indicate that changes in renal haemodynamics may not be a plausible explanation either. The finding that, during NO-clamping, GFR remained unchanged despite a robust decrease in RPF and a trend towards a decrease in arterial blood pressure is compatible with a condition of relative hyperfiltration. This could indicate that the efficacy of the TGF was reduced during the NO-clamping. An increase in NO availability in the JGA (juxtaglomerular apparatus) would inhibit TGF (for reviews, see [46, 47] ) and thereby enhance a natriuretic response [48] . If the nNOS of the macula densa were less sensitive to inhibition by l-NAME than the eNOS of the renal endothelium, then the level of NO in the JGA would be higher than that in the rest of the kidney. As mentioned above, this would most likely be associated with an increase in renin secretion (at least locally). Therefore NO-clamping may be associated with reduced sensitivity of the TGF, promoting sodium excretion, and elevated (intrarenal) RAAS activity, increasing sodium reabsorption. It may be speculated that in a dynamic situation, the reduced TGF activity leads to hypernatriuresis, but that in steady states, the effects of the elevated (intrarenal) RAAS activity prevail. At present, however, there is little evidence to support this hypothesis of selective sensitivity of different NOS isoforms to l-NAME, resulting in an imbalance between TGF and (intrarenal) RAAS activities. Future studies have to be designed more specifically to clarify the relative importance of the different renal NO signalling mechanisms in the control of total body sodium.
Conclusions
The present results clearly demonstrate the existence of hypernatriuresis during NO-clamping. Although the mechanisms remain obscure, the response is interesting phenomenologically. It has been known for many years, e.g. [49, 50] , and recently confirmed [51] that mild, monosymptomatic, essential hypertension is associated with hypernatriuresis. Other studies have demonstrated reduced renal perfusion and reduced glomerular filtration in hypertension, e.g. [52] . If NOclamping in normal subjects is associated with renal hypoperfusion, hypofiltration and hypernatriuresis, and these phenomena also are characteristics of patients with essential hypertension, it is possible that hypertension is associated with reduced renal NO availability. Notably, the hypernatriuresis present during NO-clamping and in essential hypertension may reflect abnormal NOmediated modulation of the TGF. During NO-clamping, the enzyme involved in TGF regulation (nNOS, NOS1) could be particularly sensitive to l-NAME increasing the eNOS/nNOS activity ratio in the kidney during clamping, and in hypertension an increase in renal afferent arteriolar tone could be a primary element of disease causing chronic suppression of TGF responses. It is possible to test the hypotheses that the enzyme activity ratio changes during NO-clamping and that renal, rather than extrarenal, vasoconstriction is present in essential hypertension.
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